^
Association details:
| Biomarker: | CUX1-BRAF fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
Excerpt:
Results of treatment with vemurafenib differed markedly in tumors with BRAF V600 mutations when compared with those with other BRAF mutations. Of the 26 patients with BRAF V600 mutations (all V600E), objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%) with six different tumor types (two CR, 10 PR; Table 4). In contrast, only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion).
DOI:
10.1200/JCO.2017.75.3780
Trial ID:
